Do urocortins have a role in treating cardiovascular disease?

•Urocortins could serve as alternative/adjunct therapies for cardiovascular disease.•Pre-clinical and clinical data for such uses of urocortins are promising.•Urocortins may play a role in the treatment of ischemic heart disease, hypertension and heart failure. Corticotropin-releasing factor (CRF) a...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2019-01, Vol.24 (1), p.279-284
Main Authors: Chatzaki, Ekaterini, Kefala, Nikoleta, Drosos, Ioannis, Lalidou, Fani, Baritaki, Stavroula
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Urocortins could serve as alternative/adjunct therapies for cardiovascular disease.•Pre-clinical and clinical data for such uses of urocortins are promising.•Urocortins may play a role in the treatment of ischemic heart disease, hypertension and heart failure. Corticotropin-releasing factor (CRF) and the three homolog neuropeptides, urocortin (UCN) 1, 2 and 3, are the major neuroendocrine factors implicated in the response of the body to stress. Recent evidence suggests that UCNs have a significant role in the pathogenesis and management of cardiovascular disease, such as congestive heart failure, ischemic heart disease, and hypertension. These data led to the initiation of clinical trials testing a possible role of UCNs in the diagnosis and therapy of cardiovascular disease, with encouraging results. Here, we summarize the available literature concerning the role of UCNs in the cardiovascular system, focusing on the emerging data creating a potential for clinical applications.
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2018.09.004